URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Steven Mizell Biography and Net Worth

EVP of Merck & Co., Inc.

Steve Mizell is executive vice president and chief human resources officer at Merck. He has responsibility for all aspects of human resources including talent acquisition and development, employee wellness, and diversity and inclusion.

Under Steve’s leadership, Merck has been recognized as a great place to work by Fortune, Fast Company, Working Mother, U.S. Veterans and People magazines. Steve joined Merck in 2018 from Monsanto, where he served as executive vice president, human resources, and was responsible for creating an industry-leading workplace for more than 20,000 employees around the world. Previously, he served as senior vice president and chief corporate resources officer for AdvancePCS, a pharmacy benefit management company, and has also held key human resources management roles at companies across the energy, defense, beverage and technology sectors.

Steve is currently a resident of New Jersey and Missouri. He serves on the boards of Allegion Plc. and Group 1 Automotive, and is a former board member of Oshkosh Corporation, where he chaired the human resources committee. Recognized as one of St. Louis’ most influential diverse business leaders, he is a longtime supporter of the National Kidney Foundation, Habitat for Humanity, and Youth in Need.

Steve holds a B.S. from Georgia Institute of Technology and an M.S. in management from Carnegie Mellon University. He is also certified by the National Association of Corporate Directors (NACD).

What is Steven Mizell's net worth?: The estimated net worth of Steven Mizell is at least $2.32 million as of February 2nd, 2024. Mr. Mizell owns 23,619 shares of Merck & Co., Inc. stock worth more than $2,315,843 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Mizell may own. Learn More about Steven Mizell's net worth.
How do I contact Steven Mizell?: The corporate mailing address for Mr. Mizell and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Steven Mizell's contact information.
Has Steven Mizell been buying or selling shares of Merck & Co., Inc.?: Steven Mizell has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Steven Mizell sold 50,694 shares of the business's stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a transaction totalling $6,420,395.10. Following the completion of the sale, the executive vice president now directly owns 23,619 shares of the company's stock, valued at $2,991,346.35. Learn More on Steven Mizell's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Steven Mizell Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/2/2024	Sell	50,694	$126.65	$6,420,395.10	23,619
8/14/2023	Sell	4,250	$109.01	$463,292.50	22,935
8/3/2023	Sell	4,500	$105.49	$474,705.00	27,185
5/3/2023	Sell	53,400	$119.01	$6,355,134.00	31,685
2/13/2023	Sell	1,815	$109.10	$198,016.50	33,085
2/9/2023	Sell	5,000	$107.00	$535,000.00	34,900
2/6/2023	Sell	4,436	$104.25	$462,453.00	39,900
11/10/2022	Sell	15,000	$101.42	$1,521,300.00	32,144
11/8/2022	Sell	20,000	$101.00	$2,020,000.00	32,144

Steven Mizell Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $98.05

$97.90

$99.68

50 Day Range

MA: $102.25

$96.30

$111.54

2 Week Range

Now: $98.05

$94.48

$134.63

Volume

29,272,893 shs

Average Volume

9,418,368 shs

Market Capitalization

$248.03 billion

P/E Ratio

20.56

Dividend Yield

3.02%

Beta

0.39